Inflammatory cytokines as uremic toxins: “ni son todos los que estan, ni estan todos los que son”

Toxins

Volumn 9, Issue 4, 2017, Pages

  Castillo Rodríguez, Esmeralda ^a   Pizarro Sánchez, Soledad ^a   Sanz, Ana B ^a   Ramos, Adrian M ^a   Sanchez Niño, Maria Dolores ^a   Martin Cleary, Catalina ^a   Fernandez Fernandez, Beatriz ^a   Ortiz, Alberto ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Adipokines; Chemokines; Chronic kidney disease; Decoy receptor; Inflammation; Mortality; Uremic toxins

Indexed keywords

ADALIMUMAB; ADIPONECTIN; ANAKINRA; CHEMERIN; CYTOKINE; ETANERCEPT; GOLIMUMAB; IBOCTADEKIN; INFLAMMASOME; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; TUMOR NECROSIS FACTOR; UREMIC TOXIN; TOXIN;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ATHEROSCLEROSIS; BILATERAL NEPHRECTOMY; CACHEXIA; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MACROPHAGE; NONHUMAN; PYROPTOSIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM; UREMIA;

ANIMALS; CYTOKINES; HUMANS; INFLAMMATION; RENAL INSUFFICIENCY, CHRONIC; TOXINS, BIOLOGICAL; UREMIA;

EID: 85016143156     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins9040114     Document Type: Review

References (145)

1. Wang, H.; Naghavi, M.; Allen, C.; Barber, R.M.; Bhutta, Z.A.; Carter, A.; Casey, D.C.; Charlson, F.J.; Chen, A.Z.; Coates, M.M.; et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 19802015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016, 388, 1459–1544.
2. Ortiz, A.; Covic, A.; Fliser, D.; Fouque, D.; Goldsmith, D.; Kanbay, M.; Mallamaci, F.; Massy, Z.A.; Rossignol, P.; Vanholder, R.; et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014, 383, 1831–1843.
3. Vanholder, R.; Glorieux, G. The intestine and the kidneys: A bad marriage can be hazardous. Clin. Kidney J. 2015, 8, 168–179.
4. Elewa, U.; Sanchez-Niño, M.D.; Martin-Cleary, C.; Fernandez-Fernandez, B.; Egido, J.; Ortiz, A. Cardiovascular risk biomarkers in CKD: The inflammation link and the road less traveled. Int. Urol. Nephrol. 2012, 44, 1731–1744.
5. Heine, G.H.; Ortiz, A.; Massy, Z.A.; Lindholm, B.; Wiecek, A.; Martínez-Castelao, A.; Covic, A.; Goldsmith, D.; Süleymanlar, G.; London, G.M.; et al. Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat. Rev. Nephrol. 2012, 8, 362–369.
6. Sanchez-Niño, M.D.; Benito-Martin, A.; Gonalves, S.; Sanz, A.B.; Ucero, A.C.; Izquierdo, M.C.; Ramos, A.M.; Berzal, S.; Selgas, R.; Ruíz-Ortega, M.; et al. TNF superfamily: A growing saga of kidney injury modulators. Mediat. Inflamm. 2010, 2010, 182958.
7. Vanholder, R.; De Smet, R.; Glorieux, G.; Argilés, A.; Baurmeister, U.; Brunet, P.; Clark, W.; Cohen, G.; De Deyn, P.P.; Deppisch, R.; et al. Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int. 2003, 63, 1934–1943.
8. Uremic-Toxins.org. Data Base. Available online: http://www.uremic-toxins.org/DataBase.html (accessed on 20 October 2016).
9. Duranton, F.; Cohen, G.; De Smet, R.; Rodriguez, M.; Jankowski, J.; Vanholder, R.; Argiles, A.; Abou Deif, O.; Drueke, T.; Baurmeister, U.; et al. Normal and Pathologic Concentrations of Uremic Toxins. J. Am. Soc. Nephrol. 2012, 23, 1258–1270.
10. Kohan, D.E. Role of collecting duct endothelin in control of renal function and blood pressure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2013, 305, R659–R668.
11. Sanz, A.B.; Sanchez-Niño, M.D.; Izquierdo, M.C.; Gonzalez-Espinoza, L.; Ucero, A.C.; Poveda, J.; Ruiz-Andres, O.; Ruiz-Ortega, M.; Selgas, R.; Egido, J.; Ortiz, A. Macrophages and recently identified forms of cell death. Int. Rev. Immunol. 2014, 33, 9–22.
12. Gupta, J.; Mitra, N.; Kanetsky, P.A.; Devaney, J.; Wing, M.R.; Reilly, M.; Shah, V.O.; Balakrishnan, V.S.; Guzman, N.J.; Girndt, M.; et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin. J. Am. Soc. Nephrol. 2012, 7, 1938–1946.
13. Hung, A.M.; Ellis, C.D.; Shintani, A.; Booker, C.; Ikizler, T.A. IL-1β Receptor Antagonist Reduces Inflammation in Hemodialysis Patients. J. Am. Soc. Nephrol. 2011, 22, 437–442.
14. Tanino, A.; Okura, T.; Nagao, T.; Kukida, M.; Pei, Z.; Enomoto, D.; Miyoshi, K.; Okamura, H.; Higaki, J. Interleukin-18 deficiency protects against renal interstitial fibrosis in aldosterone/salt-treated mice. Clin. Sci. 2016, 130, 1727–1739.
15. Sahar, S.; Dwarakanath, R.S.; Reddy, M.A.; Lanting, L.; Todorov, I.; Natarajan, R. Angiotensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: A novel cross-talk in the pathogenesis of atherosclerosis. Circ. Res. 2005, 96, 1064–1071.
16. Formanowicz, D.; Wanic-Kossowska, M.; Pawliczak, E.; Radom, M.; Formanowicz, P. Usefulness of serum interleukin-18 in predicting cardiovascular mortality in patients with chronic kidney disease—Systems and clinical approach. Sci. Rep. 2015, 5, 18332.
17. Robertson, M.J.; Kline, J.; Bauman, J.; Gardner, O.; Jonak, Z.; Koch, K.M.; Murray, S.C.; Weisenbach, J.; Toso, J. A phase I trial evaluating the safety and biological activity of iboctadekin (rhIL-18) in combination with rituximab in patients with CD20+ B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol. 2009, 27, 8566.
18. Ren, H.; Zhang, Y.; Yao, Y.; Guo, T.; Wang, H.; Mei, H.; Hu, Y. Association between the interleukin-6 genetic polymorphism 174 G/C and thrombosis disorder risk. Medicine 2016, 95, e4030.
19. Nechemia-Arbely, Y.; Barkan, D.; Pizov, G.; Shriki, A.; Rose-John, S.; Galun, E.; Axelrod, J.H. IL-6/IL-6R axis plays a critical role in acute kidney injury. J. Am. Soc. Nephrol. 2008, 19, 1106–1115.
20. Pecoits-Filho, R. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol. Dial. Transpl. 2002, 17, 1684–1688.
21. Memoli, B.; Grandaliano, G.; Soccio, M.; Postiglione, L.; Guida, B.; Bisesti, V.; Esposito, P.; Procino, A.; Marrone, D.; Michael, A. In Vivo Modulation of Soluble “Antagonistic” IL-6 Receptor Synthesis and Release in ESRD. J. Am. Soc. Nephrol. 2005, 16, 1099–1107.
22. Sun, J.; Axelsson, J.; Machowska, A.; Heimbürger, O.; Bárány, P.; Lindholm, B.; Lindström, K.; Stenvinkel, P.; Qureshi, A.R. Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD. Clin. J. Am. Soc. Nephrol. 2016, 11, 1163–1172.
23. Petruzzelli, M.; Schweiger, M.; Schreiber, R.; Campos-Olivas, R.; Tsoli, M.; Allen, J.; Swarbrick, M.; Rose-John, S.; Rincon, M.; Robertson, G.; et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 2014, 20, 433–447.
24. Stouthard, J.M.; Romijn, J.A.; Van der Poll, T.; Endert, E.; Klein, S.; Bakker, P.J.; Veenhof, C.H.; Sauerwein, H.P. Endocrinologic and metabolic effects of interleukin-6 in humans. Am. J. Physiol. 1995, 268, 813–819.
25. Jones, S.A.; Scheller, J.; Rose-John, S. Science in medicine Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. Cell 2011, 121, 3375–3383.
26. Swerdlow, D.I.; Holmes, M.V.; Kuchenbaecker, K.B.; Engmann, J.E.L.; Shah, T.; Sofat, R.; Guo, Y.; Chung, C.; Peasey, A.; Pfister, R.; et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: A mendelian randomisation analysis. Lancet 2012, 379, 1214–1224.
27. Ridker, P.M.; Lüscher, T.F. Anti-inflammatory therapies for cardiovascular disease. Eur. Heart J. 2014, 35, 1782–1791.
28. Ortiz, A.; Bustos, C.; Alonso, J.; Alcázar, R.; López-Armada, M.J.; Plaza, J.J.; González, E.; Egido, J. Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis. Adv. Nephrol. Necker Hosp. 1995, 24, 53–77.
29. Roach, D.R.; Bean, G.D.; Demangel, C.; France, M.P.; Briscoe, H.; Britton, W.J. TNF Regulates Chemokine Induction Essential for Cell Recruitment, Granuloma Formation, and Clearance of Mycobacterial Infection. J. Immunol. 2002, 168, 4620–4627.
30. Moreno, J.A.; Izquierdo, M.C.; Sanchez-Niño, M.D.; Suárez-Alvarez, B.; Lopez-Larrea, C.; Jakubowski, A.; Blanco, J.; Ramirez, R.; Selgas, R.; Ruiz-Ortega, M.; et al. The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. J. Am. Soc. Nephrol. 2011, 22, 1315–1325.
31. Sakurai, Y.; Zhang, X.U.; Wolfe, R.R. Short-term effects of tumor necrosis factor on energy and substrate metabolism in dogs. J. Clin. Invest. 1993, 91, 2437–2445.
32. Al-Aly, Z. Arterial calcification: A tumor necrosis factor-alpha mediated vascular Wnt-opathy. Transl. Res. 2008, 151, 233–239.
33. Hénaut, L.; Sanz, A.B.; Martin-Sanchez, D.; Carrasco, S.; Villa-Bellosta, R.; Aldamiz-Echevarria, G.; Massy, Z.A.; Sanchez-Nino, M.D.; Ortiz, A. TWEAK favors phosphate-induced calcification of vascular smooth muscle cells through canonical and non-canonical activation of NFκB. Cell Death Dis. 2016, 7, e2305.
34. Buendía, P.; De Oca, A.M.; Madueño, J.A.; Merino, A.; Martín-Malo, A.; Aljama, P.; Ramírez, R.; Rodríguez, M.; Carracedo, J. Endothelial microparticles mediate inflammation-induced vascular calcification. FASEB J. 2015, 29, 173–181.
35. Stenvinkel, P.; Ketteler, M.; Johnson, R.J.; Lindholm, B.; Pecoits-Filho, R.; Riella, M.; Heimbürger, O.; Cederholm, T.; Girndt, M. IL-10, IL-6, and TNF-α: Central factors in the altered cytokine network of uremia—The good, the bad, and the ugly. Kidney Int. 2005, 67, 1216–1233.
36. Cohen, S.D.; Phillips, T.M.; Khetpal, P.; Kimmel, P.L. Cytokine patterns and survival in haemodialysis patients. Nephrol. Dial. Transpl. 2010, 25, 1239–1243.
37. Ortiz, A.; Massy, Z.A.; Fliser, D.; Lindholm, B.; Wiecek, A.; Martínez-Castelao, A.; Covic, A.; Goldsmith, D.; Süleymanlar, G.; London, G.M.; et al. Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nat. Rev. Nephrol. 2011, 8, 141–150.
38. Gómez-Chiarri, M.; Ortíz, A.; Lerma, J.L.; López-Armada, M.J.; Mampaso, F.; González, E.; Egido, J. Involvement of tumor necrosis factor and platelet-activating factor in the pathogenesis of experimental nephrosis in rats. Lab Investig. 1994, 70, 449–459.
39. Egido, J.; Gómez-Chiarri, M.; Ortíz, A.; Bustos, C.; Alonso, J.; Gómez-Guerrero, C.; Gómez-Garre, D.; López-Armada, M.J.; Plaza, J.; Gonzalez, E. Role of tumor necrosis factor-alpha in the pathogenesis of glomerular diseases. Kidney Int. Suppl. 1993, 39, 59–64.
40. Yamanaka, H. TNF as a Target of Inflammation in Rheumatoid Arthritis. Endocr. Metab. Immune Disord. Drug Targets 2015, 15, 129–134.
41. Kim, H.W.; Lee, C.-K.; Cha, H.-S.; Choe, J.-Y.; Park, E.-J.; Kim, J. Effect of anti-tumor necrosis factor alpha treatment of rheumatoid arthritis and chronic kidney disease. Rheumatol. Int. 2015, 35, 727–734.
42. Edrees, A.F.; Misra, S.N.; Abdou, N.I. Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: Correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin. Exp. Rheumatol. 2005, 23, 469–474.
43. Don, B.R.; Kim, K.; Li, J.; Dwyer, T.; Alexander, F.; Kaysen, G.A. The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients. Clin. Nephrol. 2010, 73, 431–438.
44. Levine, S.J. Molecular mechanisms of soluble cytokine receptor generation. J. Biol. Chem. 2008, 283, 14177–14181.
45. Neirynck, N.; Glorieux, G.; Schepers, E.; Verbeke, F.; Vanholder, R. Soluble tumor necrosis factor receptor 1 and 2 predict outcomes in advanced chronic kidney disease: A prospective cohort study. PLoS ONE 2015, 10, e0122073.
46. Gohda, T.; Niewczas, M.A.; Ficociello, L.H.; Walker, W.H.; Skupien, J.; Rosetti, F.; Cullere, X.; Johnson, A.C.; Crabtree, G.; Smiles, A.M. Circulating TNF Receptors 1 and 2 Predict Stage 3 CKD in Type 1 Diabetes. J. Am. Soc. Nephrol. 2012, 23, 516–524.
47. Niewczas, M.A.; Gohda, T.; Skupien, J.; Smiles, A.M.; Walker, W.H.; Rosetti, F.; Cullere, X.; Eckfeldt, J.H.; Doria, A.; Mayadas, T.N.; et al. Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes. J. Am. Soc. Nephrol. 2012, 23, 507–515.
48. Izumi, Y.; Yabe, D.; Taniguchi, A.; Fukushima, M.; Nakai, Y.; Hosokawa, M.; Okumura, T.; Nin, K.; Matsumoto, K.; Nishimura, F.; et al. Circulating TNF receptor 2 is associated with the development of chronic kidney disease in non-obese Japanese patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2013, 99, 145–150.
49. Carlsson, A.C.; Nordquist, L.; Larsson, T.E.; Carrero, J.-J.; Larsson, A.; Lind, L.; Ärnlöv, J. Soluble Tumor Necrosis Factor Receptor 1 is Associated with Glomerular Filtration Rate Progression and Incidence of Chronic Kidney Disease in Two Community-Based Cohorts of Elderly Individuals. Cardiorenal Med. 2015, 5, 278–288.
50. Bemelmans, M.H.; Gouma, D.J.; Buurman, W.A. Tissue distribution and clearance of soluble murine TNF receptors in mice. Cytokine 1994, 6, 608–615.
51. Gardam, M.A.; Keystone, E.C.; Menzies, R.; Manners, S.; Skamene, E.; Long, R.V.D. Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect. Dis. 2003, 3, 148–155.
52. Romanowski, K.; Clark, E.G.; Levin, A.; Cook, V.J.; Johnston, J.C. Tuberculosis and chronic kidney disease: An emerging global syndemic. Kidney Int. 2016, 90, 34–40.
53. Tocci, G.; Goletti, D.; Marino, V.; Matucci, A.; Milano, G.M.; Cantini, F.; Scarpa, R. Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: A focus on rheumatoid arthritis. Expert Opin. Drug Saf. 2016, 15 (Suppl. 1), 55–61.
54. European Medicines Agency. Enbrel. Summary of Product Characteristics. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000262/WC500027361.pdf (accessed on 23 December 2016).
55. Brat, D.J.; Bellail, A.C.; Van Meir, E.G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-Oncology 2005, 7, 122–133.
56. David, J.; Dominguez, C.; Hamilton, D.; Palena, C. The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance. Vaccines 2016, 4, 22.
57. Panichi, V.; Taccola, D.; Rizza, G.M.; Consani, C.; Ghiadoni, L.; Filippi, C.; Cristofani, R.; Panicucci, E.; Migliori, M.; Sidoti, A.; et al. Interleukin-8 is a powerful prognostic predictor of all-cause and cardiovascular mortality in dialytic patients. Nephron Clin. Pract. 2006, 102, 51–59.
58. Bangsgaard, N.; Houtkamp, M.; Schuurhuis, D.H.; Parren, P.W.H.I.; Baadsgaard, O.; Niessen, H.W.M.; Skov, L. Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor. PLoS ONE 2012, 7, e39706.
59. Skov, L.; Beurskens, F.J.; Zachariae, C.O.C.; Reitamo, S.; Teeling, J.; Satijn, D.; Knudsen, K.M.; Boot, E.P.; Hudson, D.; Baadsgaard, O.; et al. IL-8 as Antibody Therapeutic Target in Inflammatory Diseases: Reduction of Clinical Activity in Palmoplantar Pustulosis. J. Immunol. 2008, 181, 669–679.
60. Oft, M. IL-10: Master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol. Res. 2014, 2, 194–199.
61. Mu, W.; Ouyang, X.; Agarwal, A.; Zhang, L.; Long, D.A.; Cruz, P.E.; Roncal, C.A.; Glushakova, O.Y.; Chiodo, V.A.; Atkinson, M.A.; et al. IL-10 Suppresses Chemokines, Inflammation, and Fibrosis in a Model of Chronic Renal Disease. J. Am. Soc. Nephrol. 2005, 16, 3651–3660.
62. Naing, A.; Papadopoulos, K.P.; Autio, K.A.; Ott, P.A.; Patel, M.R.; Wong, D.J.; Falchook, G.S.; Pant, S.; Whiteside, M.; Rasco, D.R.; et al. Safety, antitumor activity, and immune activation of pegylated recombinant human interleukin-10 (AM0010) in patients with advanced solid tumors. J. Clin. Oncol. 2016, 34, 3562–3569.
63. Tilg, H.; van Montfrans, C.; van den Ende, A.; Kaser, A.; van Deventer, S.J.H.; Schreiber, S.; Gregor, M.; Ludwiczek, O.; Rutgeerts, P.; Gasche, C.; et al. Treatment of Crohn’s disease with recombinant human interleukin-10 induces the proinflammatory cytokine interferon gamma. Gut 2002, 50, 191–195.
64. Yilmaz, M.I.; Solak, Y.; Saglam, M.; Cayci, T.; Acikel, C.; Unal, H.U.; Eyileten, T.; Oguz, Y.; Sari, S.; Carrero, J.J.; et al. The relationship between IL-10 levels and cardiovascular events in patients with CKD. Clin. J. Am. Soc. Nephrol. 2014, 9, 1207–1216.
65. Weber, C.; Sigrist, M.; Romann, A.; Chiarelli, G.; Levin, A. Novel biomarkers do not correlate with severity of vascular stiffness in ckd patients with severe co-morbid disease. Nephron Clin. Pract. 2011, 119, 261–268.
66. Irndt, M.A.G.; Lrich, C.H.U.; Aul, H.A.K.; Ester, U.R.S.; Ester, M.A.S.; Saar, H. Uremia-associated immune defect: The IL-10—CRP axis. Kidney Int. Suppl. 2003, 63, 76–79.
67. Teta, D. Adipokines as uremic toxins. J. Ren. Nutr. 2012, 22, 81–85.
68. Nagy, K.; Nagaraju, S.P.; Rhee, C.M.; Mathe, Z.; Molnar, M.Z. Adipocytokines in renal transplant recipients. Clin. Kidney J. 2016, 9, 359–373.
69. Ohashi, K.; Iwatani, H.; Kihara, S.; Nakagawa, Y.; Komura, N.; Fujita, K.; Maeda, N.; Nishida, M.; Katsube, F.; Shimomura, I.; Ito, T.; Funahashi, T. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 1910–1917.
70. Liu, M.; Liu, F. Regulation of adiponectin multimerization, signaling and function. Best Pract. Res. Clin. Endocrinol. Metab. 2014, 28, 25–31.
71. Jia, T.; Carrero, J.J.; Lindholm, B.; Stenvinkel, P. The complex role of adiponectin in chronic kidney disease. Biochimie 2012, 94, 2150–2156.
72. Zoccali, C.; Mallamaci, F.; Tripepi, G.; Benedetto, F.A.; Cutrupi, S.; Parlongo, S.; Malatino, L.S.; Bonanno, G.; Seminara, G.; Rapisarda, F.; et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J. Am. Soc. Nephrol. 2002, 13, 134–141.
73. Yu, Z.Z.; Ni, Z.H.; Gu, L.Y.; Lin, A.W.; Fang, W.; Yao, Q.; Lindholm, B.; Qian, J.Q. Adiponectin is related to carotid artery plaque and a predictor of cardiovascular outcome in a cohort of non-diabetic peritoneal dialysis patients. Blood Purif. 2008, 26, 386–393.
74. Ohashi, N.; Kato, A.; Misaki, T.; Sakakima, M.; Fujigaki, Y.; Yamamoto, T.; Hishida, A. Association of serum adiponectin levels with all-cause mortality in hemodialysis patients. Intern. Med. 2008, 47, 485–491.
75. Drechsler, C.; Krane, V.; Winkler, K.; Dekker, F.; Wanner, C. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int. 2009, 76, 567–575.
76. Zhang, F.; Chen, Y.; Heiman, M.; DiMarchi, R. Leptin: Structure, Function and Biology. Vitam. Horm. 2005, 71, 345–372.
77. Heimburger, O.; Lonnqvist, F.; Danielsson, A.; Nordenstrom, J.; Stenvinkel, P. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J. Am. Soc. Nephrol. 1997, 8, 1423–1430.
78. Sharma, K.; Ziyadeh, F.N. The emerging role of transforming growth factor-beta in kidney diseases. Am. J. Physiol. 1994, 266, 829–842.
79. Li, L.; Mamputu, J.-C.; Wiernsperger, N.; Renier, G. Signaling Pathways Involved in Human Vascular Smooth Muscle Cell Proliferation and Matrix Metalloproteinase-2 Expression Induced by Leptin. Diabetes 2005, 54, 2227–2234.
80. Sierra-Honigmann, M.R.; Nath, A.K.; Murakami, C.; García-Cardeña, G.; Papapetropoulos, A.; Sessa, W.C.; Madge, L.A.; Schechner, J.S.; Schwabb, M.B.; Polverini, P.J.; Flores-Riveros, J.R. Biological action of leptin as an angiogenic factor. Science 1998, 281, 1683–1686.
81. Wallaschofski, H.; Kobsar, A.; Sokolova, O.; Siegemund, A.; Stepan, H.; Faber, R.; Eigenthaler, M.; Lohmann, T. Differences in platelet activation by prolactin and leptin. Horm. Metab. Res. 2004, 36, 453–457.
82. Carlyle, M.; Jones, O.B.; Kuo, J.J.; Hall, J.E. Chronic cardiovascular and renal actions of leptin: Role of adrenergic activity. Hypertension 2002, 39, 496–501.
83. Tsuji, K.; Maeda, T.; Kawane, T.; Matsunuma, A.; Horiuchi, N. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1α,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J. Bone Miner. Res. 2010, 25, 1711–1723.
84. Cheung, W.W.; Ding, W.; Gunta, S.S.; Gu, Y.; Tabakman, R.; Klapper, L.N.; Gertler, A.; Mak, R.H. A Pegylated Leptin Antagonist Ameliorates CKD-Associated Cachexia in Mice. J. Am. Soc. Nephrol. 2014, 25, 119–128.
85. Cheung, W.; Yu, P.X.; Little, B.M.; Cone, R.D.; Marks, D.L.; Mak, R.H. Role of leptin and melanocortin signaling in uremia-associated cachexia. J. Clin. Invest. 2005, 115, 1659–1665.
86. Odamaki, M.; Furuya, R.; Yoneyama, T.; Nishikino, M.; Hibi, I.; Miyaji, K.; Kumagai, H. Association of the serum leptin concentration with weight loss in chronic hemodialysis patients. Am. J. Kidney Dis. 1999, 33, 361–368.
87. Castaneda-Sceppa, C.; Sarnak, M.J.; Wang, X.; Greene, T.; Madero, M.; Kusek, J.W.; Beck, G.; Kopple, J.D.; Levey, A.S.; Menon, V. Role of adipose tissue in determining muscle mass in patients with chronic kidney disease. J. Ren. Nutr. 2007, 17, 314–322.
88. Rodríguez-Carmona, A.; Pérez Fontán, M.; Cordido, F.; García Falcón, T.; García-Buela, J. Hyperleptinemia is not correlated with markers of protein malnutrition in chronic renal failure. Nephron 2000, 86, 274–280.
89. Scholze, A.; Rattensperger, D.; Zidek, W.; Tepel, M. Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. Obesity 2007, 15, 1617–1622.
90. Kalantar-Zadeh, K. So, is leptin good or bad in chronic kidney disease? Obesity 2007, 15, 1343–1344.
91. Díez, J.J.; Bossola, M.; Fernández-Reyes, M.J.; Di Stasio, E.; Tazza, L.; Luciani, G.; Codoceo, R.; Iglesias, P.; Rodríguez, A.; González, E.; et al. Relationship between leptin and all-cause and cardiovascular mortality in chronic hemodialysis patients. Nefrologia 2011, 31, 206–212.
92. Zoccali, C.; Postorino, M.; Marino, C.; Pizzini, P.; Cutrupi, S.; Tripepi, G. Waist circumference modifies the relationship between the adipose tissue cytokines leptin and adiponectin and all-cause and cardiovascular mortality in haemodialysis patients. J. Intern. Med. 2011, 269, 172–181.
93. Steppan, C.M.; Bailey, S.T.; Bhat, S.; Brown, E.J.; Banerjee, R.R.; Wright, C.M.; Patel, H.R.; Ahima, R.S.; Lazar, M.A. The hormone resistin links obesity to diabetes. Nature 2001, 409, 307–312.
94. Axelsson, J.; Bergsten, A.; Qureshi, A.R.; Heimbürger, O.; Bárány, P.; Lönnqvist, F.; Lindholm, B.; Nordfors, L.; Alvestrand, A.; Stenvinkel, P. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int. 2006, 69, 596–604.
95. Codoñer-Franch, P.; Alonso-Iglesias, E. Resistin: Insulin resistance to malignancy. Clin. Chim. Acta 2015, 438, 46–54.
96. Fontana, A.; Spadaro, S.; Copetti, M.; Spoto, B.; Salvemini, L.; Pizzini, P.; Frittitta, L.; Mallamaci, F.; Pellegrini, F.; Trischitta, V.; et al. Association between resistin levels and all-cause and cardiovascular mortality: A new study and a systematic review and meta-analysis. PLoS ONE 2015, 10, e0120419.
97. Spoto, B.; Mattace-Raso, F.; Sijbrands, E.; Pizzini, P.; Cutrupi, S.; D’Arrigo, G.; Tripepi, G.; Zoccali, C.; Mallamaci, F. Resistin and all-cause and cardiovascular mortality: Effect modification by adiponectin in end-stage kidney disease patients. Nephrol. Dial. Transpl. 2013, 28 (Suppl. 4), 181–187.
98. Roubicek, T.; Bartlova, M.; Krajickova, J.; Haluzikova, D.; Mraz, M.; Lacinova, Z.; Kudla, M.; Teplan, V.; Haluzik, M. Increased production of proinflammatory cytokines in adipose tissue of patients with end-stage renal disease. Nutrition 2009, 25, 762–768.
99. Wallquist, C.; Mansouri, L.; Norrbäck, M.; Hylander, B.; Jacobson, S.H.; Lundahl, J. Early Changes in Monocyte Adhesion Molecule Expression and Tumor Necrosis Factor-α Levels in Chronic Kidney Disease—A 5-Year Prospective Study. Am. J. Nephrol. 2016, 44, 268–275.
100. Azim, A.A.; Farag, A.S.; El-Maleek Hassan, D.A.; Abdu, S.M.; Lashin, S.M.; Abdelaziz, N. Role of Interleukin-2 in Uremic Pruritus Among Attendants of AL-Zahraa Hospital Dialysis Unit. Indian J. Dermatol. 2015, 60, 211.
101. Gaspari, A.A.; Lotze, M.T.; Rosenberg, S.A.; Stern, J.B.; Katz, S.I. Dermatologic changes associated with interleukin 2 administration. JAMA 1987, 258, 1624–1629.
102. Mehta, N.N.; Matthews, G.J.; Krishnamoorthy, P.; Shah, R.; Mclaughlin, C.; Patel, P.; Budoff, M.; Chen, J.; Wolman, M.; Go, A.; He, J.; et al. Higher plasma CXCL12 levels predict incident myocardial infarction and death in chronic kidney disease: Findings from the Chronic Renal Insufficiency Cohort study the Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Eur. Heart J. 2014, 35, 2115–2122.
103. Shah, R.; Matthews, G.J.; Shah, R.Y.; McLaughlin, C.; Chen, J.; Wolman, M.; Master, S.R.; Chai, B.; Xie, D.; Rader, D.J.; et al. Serum Fractalkine (CX3CL1) and Cardiovascular Outcomes and Diabetes: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am. J. Kidney Dis. 2015, 66, 266–273.
104. Moreno, J.A.; Moreno, S.; Rubio-Navarro, A.; Sastre, C.; Blanco-Colio, L.M.; Gómez-Guerrero, C.; Ortiz, A.; Egido, J. Targeting chemokines in proteinuria-induced renal disease. Expert Opin. Ther. Targets 2012, 16, 833–845.
105. Perez-Gomez, M.V.; Sanchez-Niño, M.D.; Sanz, A.B.; Zheng, B.; Martín-Cleary, C.; Ruiz-Ortega, M.; Ortiz, A.; Fernandez-Fernandez, B. Targeting inflammation in diabetic kidney disease: early clinical trials. Expert Opin. Investig. Drugs 2016, 3784, 1–14.
106. Uchida, E.; Anan, F.; Masaki, T.; Kaneda, K.; Nawata, T.; Eshima, N.; Saikawa, T.; Yoshimatsu, H. Monocyte chemoattractant protein-1 is associated with silent cerebral infarction in patients on haemodialysis. Intern. Med. J. 2012, 42, 29–34.
107. Elewa, U.; Sanchez-Niño, M.D.; Mahillo-Fernández, I.; Martin-Cleary, C.; Sanz, A.B.; Perez-Gomez, M.V.; Fernandez-Fernandez, B.; Ortiz, A. Circulating CXCL16 in Diabetic Kidney Disease. Kidney Blood Press Res. 2016, 41, 663–671.
108. Izquierdo, M.C.; Sanz, A.B.; Mezzano, S.; Blanco, J.; Carrasco, S.; Sanchez-Niño, M.D.; Benito-Martín, A.; Ruiz-Ortega, M.; Egido, J.; Ortiz, A. TWEAK (tumor necrosis factor–like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation. Kidney Int. 2012, 81, 1098–1107.
109. Izquierdo, M.C.; Martin-Cleary, C.; Fernandez-Fernandez, B.; Elewa, U.; Sanchez-Niño, M.D.; Carrero, J.J.; Ortiz, A. CXCL16 in kidney and cardiovascular injury. Cytokine Growth Factor Rev. 2014, 25, 317–325.
110. Yilmaz, M.I.; Sonmez, A.; Ortiz, A.; Saglam, M.; Kilic, S.; Eyileten, T.; Caglar, K.; Oguz, Y.; Vural, A.; Çakar, M. Soluble TWEAK and PTX3 in nondialysis CKD patients: Impact on endothelial dysfunction and cardiovascular outcomes. Clin. J. Am. Soc. Nephrol. 2011, 6, 785–792.
111. Carrero, J.J.; Ortiz, A.; Qureshi, A.R.; Martín-Ventura, J.L.; Bárány, P.; Heimbürger, O.; Marrón, B.; Metry, G.; Snaedal, S.; Lindholm, B.; et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2009, 4, 110–118.
112. Yilmaz, M.I.; Carrero, J.J.; Ortiz, A.; Martín-Ventura, J.L.; Sonmez, A.; Saglam, M.; Yaman, H.; Yenicesu, M.; Egido, J.; Blanco-Colio, L.M. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009, 4, 1716–1723.
113. Ruiz-Ortega, M.; Ortiz, A.; Ramos, A.M. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and kidney disease. Curr. Opin. Nephrol. Hypertens. 2014, 23, 93–100.
114. Sanz, A.B.; Izquierdo, M.C.; Sanchez-Niño, M.D.; Ucero, A.C.; Egido, J.; Ruiz-Ortega, M.; Ramos, A.M.; Putterman, C.; Ortiz, A. TWEAK and the progression of renal disease: Clinical translation. Nephrol. Dial. Transpl. 2014, 29 (Suppl. 1), i54–i62.
115. Duan, D.M.; Niu, J.M.; Lei, Q.; Lin, X.H.; Chen, X. Serum levels of the adipokine chemerin in preeclampsia. J. Perinat. Med. 2012, 40, 121–127.
116. Yamamoto, T.; Qureshi, A.R.; Anderstam, B.; Heimbürger, O.; Bárány, P.; Lindholm, B.; Stenvinkel, P.; Axelsson, J. Clinical importance of an elevated circulating chemerin level in incident dialysis patients. Nephrol. Dial. Transpl. 2010, 25, 4017–4023.
117. Chen, H.-Y.; Chiu, Y.-L.; Hsu, S.-P.; Pai, M.-F.; Yang, J.-Y.; Wu, H.-Y.; Peng, Y.S. Reappraisal of effects of serum chemerin and adiponectin levels and nutritional status on cardiovascular outcomes in prevalent hemodialysis patients. Sci Rep. 2016, 6, 34128.
118. Neves, K.B.; Nguyen Dinh Cat, A.; Lopes, R.A.M.; Rios, F.J.; Anagnostopoulou, A.; Lobato, N.S.; de Oliveira, A.M.; Tostes, R.C.; Montezano, A.C.; Touyz, R.M. Chemerin Regulates Crosstalk between Adipocytes and Vascular Cells Through Nox. Hypertension 2015, 66, 657–666.
119. Axelsson, J.; Witasp, A.; Carrero, J.J.; Qureshi, A.R.; Suliman, M.E.; Heimbürger, O.; Bárány, P.; Lindholm, B.; Alvestrand, A.; Schalling, M.; et al. Circulating Levels of Visfatin/Pre-B-Cell Colony-Enhancing Factor 1 in Relation to Genotype, GFR, Body Composition, and Survival in Patients With CKD. Am. J. Kidney Dis. 2007, 49, 237–244.
120. Hsu, C.Y.; Huang, P.H.; Chen, T.H.; Chiang, C.H.; Leu, H.B.; Huang, C.C.; Chen, J.W.; Lin, S.J. Increased circulating visfatin is associated with progression of kidney disease in non-diabetic hypertensive patients. Am. J. Hypertens. 2016, 29, 528–536.
121. Benito-Martin, A.; Ucero, A.C.; Izquierdo, M.C.; Santamaria, B.; Picatoste, B.; Carrasco, S.; Lorenzo, O.; Ruiz-Ortega, M.; Egido, J.; Ortiz, A. Endogenous NAMPT dampens chemokine expression and apoptotic responses in stressed tubular cells. Biochim. Biophys. Acta Mol. Basis Dis. 2014, 1842, 293–303.
122. Ruiz-Andres, O.; Sanchez-Niño, M.D.; Moreno, J.A.; Ruiz-Ortega, M.; Ramos, A.M.; Sanz, A.B.; Ortiz, A. Downregulation of kidney protective factors by inflammation: Role of transcription factors and epigenetic mechanisms. Am. J. Phys. Ren. Physiol. 2016, 311, 1329–1340.
123. Kakuta, T.; Komaba, H.; Takagi, N.; Takahashi, Y.; Suzuki, H.; Hyodo, T.; Nagaoka, M.; Tanaka, R.; Iwao, S.; Ishida, M.; et al. A Prospective Multicenter Randomized Controlled Study on Interleukin-6 Removal and Induction by a new Hemodialyzer with Improved Biocompatibility in Hemodialysis Patients: A Pilot Study. Ther. Apher. Dial. 2016, 20, 569–578.
124. Lee, W.C.; Uchino, S.; Fealy, N.; Baldwin, I.; Panagiotopoulos, S.; Goehl, H.; Morgera, S.; Neumayer, H.H.; Bellomo, R. Super high flux hemodialysis at high dialysate flows: An ex vivo assessment. Int. J. Artif. Organs 2004, 27, 24–28.
125. Morgera, S.; Slowinski, T.; Melzer, C.; Sobottke, V.; Vargas-Hein, O.; Volk, T.; Zuckermann-Becker, H.; Wegner, B.; Müller, J.M.; Baumann, G.; et al. Renal Replacement Therapy with High-Cutoff Hemofilters: Impact of Convection and Diffusion on Cytokine Clearances and Protein Status. Am. J. Kidney Dis. 2004, 43, 444–453.
126. Ferraiolo, B.L.; Moore, J.A.; Crase, D.; Gribling, P.; Wilking, H.; Baughman, R.A. Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice. Drug Metab. Dispos. 1988, 16, 270–275.
127. Deaciuc, I.V.; Alappat, J.M.; McDonough, K.H.; D’Souza, N.B. Effect of chronic alcohol consumption by rats on tumor necrosis factor-alpha and interleukin-6 clearance in vivo and by the isolated, perfused liver. Biochem. Pharmacol. 1996, 52, 891–899.
128. Reimers, J.; Wogensen, L.D.; Welinder, B.; Hejnaes, K.R.; Poulsen, S.S.; Nilsson, P.; Nerup, J. The pharmacokinetics, distribution and degradation of human recombinant interleukin 1 beta in normal rats. Scand. J. Immunol. 1991, 34, 597–610.
129. Ferraiolo, B.L.; McCabe, J.; Hollenbach, S.; Hultgren, B.; Pitti, R.; Wilking, H. Pharmacokinetics of recombinant human tumor necrosis factor-alpha in rats. Effects of size and number of doses and nephrectomy. Drug Metab. Dispos. 1989, 17, 369–372.
130. Beutler, B.A.; Milsark, I.W.; Cerami, A. Cachectin/tumor necrosis factor: Production, distribution, and metabolic fate in vivo. J. Immunol. 1985, 135, 3972–3977.
131. Klapproth, J.; Geiger, T.; Heinrich, P.C. Fate and biological action of human recombinant interleukin l Beta in the rat in vivo. Eur. J. Immunol. 1989, 19, 1485–1490.
132. Castell, J.V.; Geiger, T.; Gross, V.; Andus, T.; Walter, E.; Hirano, T.; Kishimoto, T.; Heinrich, P.C. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur. J. Biochem. 1988, 177, 357–361.
133. Banks, R.E.; Forbes, M.A.; Hallam, S.; Jenkins, A.; Wadhwa, M.; Dilger, P.; Meager, A.; Thorpe, R.; Bowmer, C.J.; Joffe, J.K.; et al. Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: Evidence for non-renal clearance of cytokines. Br. J. Cancer 1997, 75, 1842–1848.
134. Poveda, J.; Sanchez-Niño, M.D.; Glorieux, G.; Sanz, A.B.; Egido, J.; Vanholder, R.; Ortiz, A. P-Cresyl sulphate has pro-inflammatory and cytotoxic actions on human proximal tubular epithelial cells. Nephrol. Dial. Transpl. 2014, 29, 56–64.
135. Rossi, M.; Campbell, K.L.; Johnson, D.W.; Stanton, T.; Vesey, D.A.; Coombes, J.S.; Weston, K.S.; Hawley, C.M.; McWhinney, B.C.; Ungerer, J.P. Protein-bound uremic toxins, inflammation and oxidative stress: A cross-sectional study in stage 3–4 chronic kidney disease. Arch. Med. Res. 2014, 45, 309–317.
136. Garibotto, G.; Sofia, A.; Procopio, V.; Villaggio, B.; Tarroni, A.; Di Martino, M.; Cappelli, V.; Gandolfo, M.T.; Aloisi, F.; De Cian, F.; et al. Peripheral tissue release of interleukin-6 in patients with chronic kidney diseases: Effects of end-stage renal disease and microinflammatory state. Kidney Int. 2006, 70, 384–390.
137. Oettinger, C.W.; Bland, L.A.; Oliver, J.C.; Arduino, M.J.; McAllister, S.K.; Favero, M.S. The effect of uremia on tumor necrosis factor-alpha release after an in vitro whole-blood endotoxin challenge. J. Am. Soc. Nephrol. 1994, 4, 1890–1895.
138. Stinghen, A.E.M.; Gonçalves, S.M.; Martines, E.G.; Nakao, L.S.; Riella, M.C.; Aita, C.A.; Pecoits-Filho, R. Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron Clin. Pract. 2009, 111, c117–c126.
139. Aminzadeh, M.A.; Pahl, M.V.; Barton, C.H.; Doctor, N.S.; Vaziri, N.D. Human uraemic plasma stimulates release of leptin and uptake of tumour necrosis factor-α in visceral adipocytes. Nephrol. Dial. Transpl. 2009, 24, 3626–3631.
140. Kalbacher, E.; Koppe, L.; Zarrouki, B.; Pillon, N.J.; Fouque, D.; Soulage, C.O. Human uremic plasma and not urea induces exuberant secretion of leptin in 3T3-L1 adipocytes. J. Ren. Nutr. 2011, 21, 72–75.
141. Apolito, M.D.; Du, X.; Zong, H.; Catucci, A.; Maiuri, L.; Trivisano, T.; Pettoello-Mantovani, M.; Campanozzi, A.; Raia, V.; Pessin, J.E.; et al. Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. Insulin 2010, 120, 203–213.
142. Sanz, A.B.; Sanchez-Niño, M.D.; Ramos, A.M.; Moreno, J.A.; Santamaria, B.; Ruiz-Ortega, M.; Egido, J.; Ortiz, A. NF-κB in Renal Inflammation. J. Am. Soc. Nephrol. 2010, 21, 1254–1262.
143. Poveda, J.; Tabara, L.C.; Fernandez-Fernandez, B.; Martin-Cleary, C.; Sanz, A.B.; Selgas, R.; Ortiz, A.; Sanchez-Niño, M.D. TWEAK/Fn14 and non-canonical NF-kappaB signaling in kidney disease. Front. Immunol. 2013, 4, 447.
144. Sánchez, L.M.; López-Otín, C.; Bjorkman, P.J. Biochemical characterization and crystalization of human Zn-alpha2-glycoprotein, a soluble class I major histocompatibility complex homolog. Proc. Natl. Acad. Sci. USA 1997, 94, 4626–4630.
145. Pelletier, C.C.; Koppe, L.; Alix, P.M.; Kalbacher, E.; Croze, M.L.; Hadj-Aissa, A.; Fouque, D.; Guebre-Egziabher, F.S.C. The relationship between renal function and plasma concentration of the cachectic factor zinc-alpha2-glycoprotein (ZAG) in adult patients with chronic kidney disease. PLoS ONE 2014, 9, e103475.